36. Caron H, Vansluis P, Dekraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable

outcome in patients with neuroblastoma. N Engl J Med 1996;334(4):225–230.

37. Bown N, Cotterill S, Łastowska M, et al. Gain of chromosome arm 17q and adverse outcome in

patients with neuroblastoma. N Engl J Med 1999;340(25):1954–1961.

38. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin

North Am 2010;24(1):65–86.

39. Attiyeh EF, London WB, Mossé YP, et al. Chromosome 1p and 11q deletions and outcome in

neuroblastoma. N Engl J Med 2005;353(21):2243–2253.

40. Riley RD, Heney D, Jones DR, et al. A systematic review of molecular and biological tumor

3107

markers in neuroblastoma. Clin Cancer Res 2004;10(1):4–12.

41. Newton ER, Louis F, Dalton ME, et al. Fetal neuroblastoma and catecholamine-induced maternal

hypertension. Obstet Gynecol 1985; 65(3 suppl):49S–52S.

42. Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma:

clinical outcome and antineuronal antibodies—a report from the children’s cancer group study. Med

Pediatr Oncol 2001;36(6):612–622.

43. Russo C, Cohn SL, Petruzzi MJ, et al. Long term neurologic outcome in children with opsoclonus

myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr

Oncol 1997;28(4):284–288.

44. Holgersen LO, Subramanian S, Kirpekar M, et al. Spontaneous resolution of antenatally diagnosed

adrenal masses. J Pediatr Surg 1996;31(1):153–155.

45. Acharya S, Jayabose S, Kogan SJ, et al. Prenatally diagnosed neuroblastoma. Cancer

1997;80(2):304–310.

46. Sauvat F, Sarnacki S, Brisse H, et al. Outcome of suprarenal localized masses diagnosed during the

perinatal period: a retrospective multicenter study. Cancer 2002;94(9):2474–2480.

47. Nuchtern JG, London WB, Barnewolt CE, et al. A prospective study of expectant observation as

primary therapy for neuroblastoma in young infants. Ann Surg 2012;256(4):573–580.

48. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma

diagnosis, staging, and response to treatment. J Clin Oncol 1993;11(8):1466–1477.

49. Hann HW, Evans AE, Cohen IJ, et al. Biologic differences between neuroblastoma stages IV-S and

IV. Measurement of serum ferritin and E-rosette inhibition in 30 children. N Engl J Med

1981;305(8):425–429.

50. Zeltzer PM, Marangos PJ, Evans AE, et al. Serum neuron-specific enolase in children with

neuroblastoma. Relationship to stage and disease course. Cancer 1986;57(6):1230–1234.

51. Yanik GA. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative

chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol

2002;20(8):2142–2149.

52. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG)

staging system: an INRG Task Force report. J Clin Oncol 2009;27(2):298–303. Available at:

http://inrgdb.org/neuroblastoma-information/staging-system/

53. Cecchetto G, Mosseri V, De Bernardi B, et al. Surgical risk factors in primary surgery for localized

neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology

Neuroblastoma Group. J Clin Oncol 2005;23(33):8483–8489.

54. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG)

classification system: an INRG Task Force Report. J Clin Oncol 2009;27(2):289–297. Available at:

http://inrgdb.org/neuroblastoma-information/classification-system/

55. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II

neuroblastoma treated with surgery as primary therapy: a children’s cancer group study. J Clin

Oncol 2000;18(1):18–26.

56. Strother DR, London WB, Schmidt ML, et al. Outcome after surgery alone or with restricted use of

chemotherapy for patients with low-risk neuroblastoma: results of Children’s Oncology Group study

P9641. J Clin Oncol 2012;30(15):1842–1848.

57. Adkins ES, Sawin R, Gerbing RB, et al. Efficacy of complete resection for high-risk neuroblastoma:

a Children’s Cancer Group study. J Pediatr Surg 2004;39(6):931–936.

58. Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk

neuroblastoma. N Engl J Med 2010; 363(14):1313–1323.

59. Twist C, London WB, Naranjo A, et al. Maintaining outstanding outcomes using response-and

biology-based therapy for intermediate -risk neuroblastoma: a report from the Children’s Oncology

Group Study ANBL0531. J Clin Oncol 2014;32(15s):10006.

60. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive

chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13- cis-retinoic acid. N

Engl J Med 1999;341(16):1165–1173.

61. Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma

patients over the age of one year treated with megatherapy and stem-cell transplantation: a report

3108

from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998;

16(3):953–965.

62. La Quaglia MP, Kushner BH, Su W, et al. The impact of gross total resection on local control and

survival in high-risk neuroblastoma. J Pediatr Surg 2004;39(3):412–417.

63. Malek MM, Mollen KP, Kane TD, et al. Thoracic neuroblastoma: a retrospective review of our

institutional experience with comparison of the thoracoscopic and open approaches to resection. J

Pediatr Surg 2010;45(8):1622–1626.

64. DeCou JM, Schlatter MG, Mitchell DS. Primary thoracoscopic gross total resection of

neuroblastoma. J Laparoendosc Adv Surg Tech A 2005; 15(5):470–473.

65. Pranikoff T, Hirschl RB, Schnaufer L. Approach to cervicothoracic neuroblastomas via a trap-door

incision. J Pediatr Surg 1995;30(4):546–548.

66. Simon T, Hero B, Bongartz R, et al. Intensified external-beam radiation therapy improves the

outcome of stage 4 neuroblastoma in children >1 year with residual local disease. Strahlenther

Onkol 2006;182(7):389–394.

67. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue

versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk

neuroblastoma: a randomized controlled trial. Lancet Oncol 2005;6(9):649–658.

68. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem

autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin

Oncol 2006;24(18):2891–2896.

69. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and

isotretinoin for neuroblastoma. N Engl J Med 2010;363(14):1324–1334.

70. Simon T, Hero B, Faldum A, et al. Long term outcome of high-risk neuroblastoma patients after

immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer

2011;11(1):21.

71. Shusterman S, London WB, Gillies SD, et al. Antitumor activity of Hu14.18-IL2 in patients with

relapsed/refractory neuroblastoma: a Children’s Oncology Group (COG) phase II study. J Clin Oncol

2010; 28(33):4969–4975.

72. DuBois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of

neuroblastoma. Nucl Med Biol 2008;35:S35–S48.

73. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior

therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J

Clin Oncol 2007; 25(9):1054–1060.

74. Fernandes ET, Kumar M, Douglass EC, et al. Extrarenal Wilms’ tumor. J Pediatr Surg

1989;24(5):483–485.

75. Stiller CA, Parkin DM. International variations in the incidence of childhood renal tumours. Br J

Cancer 1990;62(6):1026.

76. Breslow NE, Beckwith JB. Epidemiological features of Wilms’ tumor: results of the National Wilms’

tumor study. J Natl Cancer Inst 1982;68(3):429–436.

77. Kim S, Chung DH. Pediatric solid malignancies: neuroblastoma and Wilms’ tumor. Surg Clin North

Am 2006;86(2):469–487.

78. Slater RM, Mannens MM. Cytogenetics and molecular genetics of Wilms’ tumor of childhood.

Cancer Genet Cytogenet 1992;61(2):111–121.

79. Pritchard-Jones K. Malignant origin of the stromal component of Wilms’ tumor. J Natl Cancer Inst

1997;89(15):1089–1091.

80. Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomatosis, and the pathogenesis

of Wilms’ tumor. Pediatr Pathol 1990;10(1–2):1–36.

81. Rivera MN, Haber DA. Wilms’ tumour: connecting tumorigenesis and organ development in the

kidney. Nat Rev Cancer 2005;5(9):699–712.

82. Pritchard Jones K, Vujanic G. Multiple pathways to Wilms tumor: how much is genetic? Pediatr

Blood Cancer 2006;47(3):232–234.

83. Coppes MJ, Campbell C, Williams BR. Genetics of Wilms tumor. In: Wilms Tumor: Clinical and

Molecular Characterization. Vol Molecular Biology Intelligence Unit. Berlin, Heidelberg: Springer Berlin

Heidelberg; 1995:41–56.

3109

84. Weirich A, Leuschner I, Harms D, et al. Clinical impact of histologic subtypes in localized nonanaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH. Ann Oncol

2001;12(3):311–319.

85. Bonadio JF, Storer B, Norkool P, et al. Anaplastic Wilms’ tumor: clinical and pathologic studies. J

Clin Oncol 1985;3(4):513–520.

86. Faria P, Beckwith JB, Mishra K, et al. Focal versus diffuse anaplasia in Wilms tumor—new

definitions with prognostic significance: a report from the National Wilms Tumor Study Group. Am

J Surg Pathol 1996;20(8):909.

87. Beckwith JB. Wilms tumor and other renal tumors of childhood: a selective review from the

National Wilms Tumor Study Pathology Center. Human Pathol 1983;14(6):481–492.

88. Beckwith JB. Precursor lesions of Wilms tumor: clinical and biological implications. Med Pediatr

Oncol 1993;21(3):158–168.

89. Grundy PE, Telzerow PE, Breslow N, et al. Loss of heterozygosity for chromosomes 16q and 1p in

Wilms’ tumors predicts an adverse outcome. Cancer Res 1994;54(9):2331–2333.

90. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an

adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms

Tumor Study Group. J Clin Oncol 2005;23(29):7312–7321.

91. Wilimas JA, Kaste SC, Kauffman WM, et al. Use of chest computed tomography in the staging of

pediatric Wilms’ tumor: interobserver variability and prognostic significance. J Clin Oncol

1997;15(7):2631–2635.

92. Owens CM, Veys PA, Pritchard J, et al. Role of chest computed tomography at diagnosis in the

management of Wilms’ tumor: a study by the United Kingdom Children’s Cancer Study Group. J

Clin Oncol 2002; 20(12):2768–2773.

93. Ehrlich PF, Hamilton TE, Grundy P, et al. The value of surgery in directing therapy for patients

with Wilms’ tumor with pulmonary disease. A report from the National Wilms’ Tumor Study Group

(National Wilms’ Tumor Study 5). J Pediatr Surg 2006;41(1):162–167; discussion 162–167.

94. Neville HL, Ritchey ML. Wilms’ Tumor. Urol Clin North Am 2000; 27(3):435–442.

95. Pritchard-Jones K, Kelsey A, Vujanic G, et al. Older age is an adverse prognostic factor in stage I,

favorable histology Wilms’ tumor treated with vincristine monochemotherapy: a study by the

United Kingdom Children’s Cancer Study Group, Wilms’ Tumor Working Group. J Clin Oncol 2003;

21(17):3269–3275.

96. Zuppan CW, Weeks DA, Bruce Beckwith J, et al. The effect of preoperative therapy on the

histologic features of Wilms tumor. An analysis of cases from the third national Wilms tumor study.

Cancer 1991;68(2):385–394.

97. Tournade MF, Com-Nougué C, de Kraker J, et al. Optimal duration of preoperative therapy in

unilateral and nonmetastatic Wilms tumor in children older than 6 months: results of the Ninth

International Society of Pediatric Oncology Wilms’ Tumor Trial and Study. J Clin Oncol

2001;19(2):488–500.

98. D’Angio GJ, Evans AE, Breslow N, et al. The treatment of Wilms tumor. Results of the national

Wilms tumor study. Cancer 1976;38(2):633–646.

99. D’Angio GJ, Evans A, Breslow N, et al. The treatment of Wilms Tumor: results of the second

national Wilms tumor study. Cancer 1981;47(9):2302–2311.

100. D’Angio GJ, Breslow N, Beckwith JB, et al. Treatment of Wilms tumor. Results of the third national

Wilms’ tumor study. Cancer 1989;64(2):349–360.

101. Green DM, Breslow NE, Beckwith JB, et al. Comparison between single-dose and divided-dose

administration of dactinomycin and doxorubicin for patients with Wilms tumor: a report from the

National Wilms Tumor Study Group. J Clin Oncol 1998;16(1):237–245.

102. Green DM, Breslow NE, Beckwith JB, et al. Effect of duration of treatment on treatment outcome

and cost of treatment for Wilms tumor: a report from the National Wilms Tumor Study Group. J

Clin Oncol 1998; 16(12):3744–3751.

103. Davidoff AM. Wilms’ tumor. Curr Opin Pediatr 2009;21(3):357–364.

104. Metzger ML, Dome JS. Current therapy for Wilms’ tumor. Oncologist 2005;10(10):815–826.

105. Shamberger RC, Anderson JR, Breslow NE, et al. Long-term outcomes of infants with very low risk

Wilms tumor treated with surgery alone on National Wilms Tumor Study-5. Ann Surg

3110

2010;251(3):555–558.

106. Ko EY, Ritchey ML. Current management of Wilms’ tumor in children. J Pediatr Urol 2009;5(1):56–

65.

107. Shamberger RC, Guthrie KA, Ritchey ML, et al. Surgery-related factors and local recurrence of

Wilms tumor in National Wilms Tumor Study 4. Ann Surg 1999;229(2):292–297.

108. Kieran K, Ehrlich PF. Current surgical standards of care in Wilms tumor. Urol Oncol 2015;34(1):13–

23.

109. Duarte RJ, Dénes FT, Cristofani LM, et al. Laparoscopic nephrectomy for Wilms’ tumor. Expert Rev

Anticancer Ther 2014;9(6):753–761.

110. Ritchey M. Surgical complications after primary nephrectomy for Wilms tumor: report from the

National Wilms Tumor Study Group. J Am Coll Surg 2001;192(1):63–68.

111. Ritchey ML, Green DM, Thomas PR, et al. Renal failure in Wilms tumor patients: a report from the

National Wilms Tumor Study Group. Med Pediatr Oncol 1996;26(2):75–80.

112. Shamberger RC, Ritchey ML, Haase GM, et al. Intravascular extension of Wilms tumor. Ann Surg

2001;234(1):116–121.

113. Szavay P, Luithle T, Semler O, et al. Surgery of cavoatrial tumor thrombus in nephroblastoma: a

report of the SIOP/GPOH study. Pediatr Blood Cancer 2004;43(1):40–45.

114. Hamilton TE, Ritchey ML, Argani P, et al. Synchronous bilateral Wilms tumor with complete

radiographic response managed without surgical resection: a report from the National Wilms’

Tumor Study 4. J Pediatr Surg 2008;43(11):1982–1984.

115. Horwitz JR, Ritchey ML, Moksness J, et al. Renal salvage procedures in patients with synchronous

bilateral Wilms tumors: a report from the National Wilms Tumor Study Group. J Pediatr Surg

1996;31(8):1020–1025.

116. Nakamura L, Ritchey M. Current management of Wilms’ tumor. Curr Urol Rep 2010;11(1):58–65.

117. Charlton J, Pavasovic V, Pritchard Jones K. Biomarkers to detect Wilms tumors in pediatric

patients: where are we now? Future Oncol 2015; 11(15):2221–2234.

118. Wegert J, Ishaque N, Vardapour R, et al. Mutations in the SIX1/2 pathway and the

DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors.

Cancer Cell 2015;27(2):298–311.

119. Maschietto M, Charlton J, Perotti D, et al. The IGF signalling pathway in Wilms tumours—a report

from the ENCCA Renal Tumours Biology-driven drug development workshop. Oncotarget

2014;5(18):8014–8026.

120. Sakamoto Y, Mariya Y, Sasaki S, et al. WT1 mRNA level in peripheral blood is a sensitive

biomarker for monitoring minimal residual disease in acute myeloid leukemia. Tohoku J Exp Med

2009;219(2):169–176.

121. van den Heuvel-Eibrink MM, Grundy P, Graf N, et al. Characteristics and survival of 750 children

diagnosed with a renal tumor in the first seven months of life: a collaborative study by the

SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups. Pediatr Blood Cancer

2008;50(6):1130–1134.

122. Wang Z-P, Li K, Dong K-R, et al. Congenital mesoblastic nephroma: clinical analysis of eight cases

and a review of the literature. Oncol Lett 2014;8(5):2007–2011.

123. Glick RD, Hicks MJ, Nuchtern JG, et al. Renal tumors in infants less than 6 months of age. J Pediatr

Surg 2004;39(4):522–525.

124. Whittle S, Gosain A, Brown PY, et al. Regression of a congenital mesoblastic nephroma. Pediatr

Blood Cancer 2010;55(2):364–368.

125. Knezevich SR, Garnett MJ, Pysher TJ, et al. ETV6-NTRK3 gene fusions and trisomy 11 establish a

histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res

1998;58(22):5046–5048.

126. Mascarello JT, Cajulis TR, Krous HF, et al. Presence or absence of trisomy 11 is correlated with

histologic subtype in congenital mesoblastic nephroma. Cancer Genet Cytogenet 1994;77(1):50–54.

127. Howell CG, Othersen HB, Kiviat NE, et al. Therapy and outcome in 51 children with mesoblastic

nephroma: a report of the national Wilms’ tumor study. J Pediatr Surg 1982;17(6):826–831.

128. Haddad B, Haziza J, Touboul C, et al. The congenital mesoblastic nephroma: a case report of

prenatal diagnosis. Fetal Diagn Ther 1996;11(1):61–66.

3111

129. Argani P, Perlman EJ, Breslow NE, et al. Clear cell sarcoma of the kidney: a review of 351 cases

from the National Wilms Tumor Study Group Pathology Center. Am J Surg Pathol 2000;24(1):4.

130. Beckwith JB, Larson E. Case 7 clear cell sarcoma of kidney. Fetal Pediatr Pathol 1989;9(2):211–218.

131. Seibel NL, Sun J, Anderson JR, et al. Outcome of clear cell sarcoma of the kidney (CCSK) treated

on the National Wilms Tumor Study-5 (NWTS). J Clin Oncol 2006;24(18s):9000.

132. Waldron PE, Rodgers BM, Kelly MD, et al. Successful treatment of a patient with stage IV rhabdoid

tumor of the kidney: case report and review. J Pediatr Hematol Oncol 1999;21(1):53–57.

133. Weeks DA, Beckwith JB, Mierau GW, et al. Rhabdoid tumor of kidney: a report of 111 cases from

the National Wilms’ Tumor Study Pathology Center. Am J Surg Pathol 1989;13(6):439.

134. Tomlinson GE, Breslow NE, Dome J, et al. Rhabdoid tumor of the kidney in the National Wilms’

Tumor Study: age at diagnosis as a prognostic factor. J Clin Oncol 2005;23(30):7641–7645.

135. Versteege I, Sévenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric

cancer. Nature 1998;394(6689):203–206.

136. Biegel JA, Fogelgren B, Wainwright LM, et al. Germline INI1 mutation in a patient with a central

nervous system atypical teratoid tumor and renal rhabdoid tumor. Genes Chromosomes Cancer

2000;28(1):31–37.

137. Biegel JA, Tan L, Zhang F, et al. Alterations of the hSNF5/INI1 gene in central nervous system

atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res

2002;8(11):3461–3467.

138. Argani P, Laé M, Ballard ET, et al. Translocation carcinomas of the kidney after chemotherapy in

childhood. J Clin Oncol 2006;24(10):1529–1534.

139. Akhavan A, Richards M, Shnorhavorian M, et al. Renal cell carcinoma in children, adolescents and

young adults: a National Cancer Database Study. J Urol 2015;193(4):1336–1341.

140. O’Toole KM, Brown M, Hoffmann P. Pathology of benign and malignant kidney tumors. Urol Clin

North Am 1993;20(2):193–205.

141. Carcao MD, Taylor GP, Greenberg ML, et al. Renal-cell carcinoma in children: a different disorder

from its adult counterpart? Med Pediatr Oncol 1998;31(3):153–158.

142. Cubilla AL, Dillner J, Schellhammer PF. World Health Organization Classification of Tumors. Pathology

and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC; 2004:281–

290:chap 5.

143. Young EE, Brown CT, Merguerian PA, et al. Pediatric and adolescent renal cell carcinoma. Urol

Oncol 2015;34(1):42–49.

144. Geller JI, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal

cell carcinoma. Cancer 2004;101(7):1575–1583.

145. Renshaw AA, Granter SR, Fletcher JA, et al. Renal cell carcinomas in children and young adults:

increased incidence of papillary architecture and unique subtypes. Am J Surg Pathol 1999;23(7):795–

802.

146. Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: workgroup no. 3. Union

International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC).

Cancer 1997;80(5):992–993.

147. Indolfi P, Terenziani M, Casale F, et al. Renal cell carcinoma in children: a clinicopathologic study.

J Clin Oncol 2003;21(3):530–535.

148. Selle B, Furtwängler R, Graf N, et al. Population-based study of renal cell carcinoma in children in

Germany, 1980–2005. Cancer 2006;107(12):2906–2914.

149. Perez EA, Kassira N, Cheung MC, et al. Rhabdomyosarcoma in children: a SEER population based

study. J Surg Res 2011;170(2):e243–e251.

150. Joshi D, Anderson JR, Paidas C, et al. Age is an independent prognostic factor in

rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children’s oncology

group. Pediatr Blood Cancer 2004;42(1):64–73.

151. Ruymann FB, Maddux HR, Ragab A, et al. Congenital anomalies associated with

rhabdomyosarcoma: an autopsy study of 115 cases. A report from the intergroup

rhabdomyosarcoma study committee (representing the children’s cancer study group, the pediatric

oncology group, the United Kingdom children’s cancer study group, and the pediatric intergroup

statistical center). Med Pediatr Oncol 1988;16(1):33–39.

3112

152. Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?

Ann Intern Med 1969;71(4):747–752.

153. McKeen EA, Bodurtha J, Meadows AT, et al. Rhabdomyosarcoma complicating multiple

neurofibromatosis. J Pediatr 1978;93(6):992–993.

154. D’Agostino AN, Soule EH, Miller RH. Sarcomas of the peripheral nerves and somatic soft tissues

associated with multiple neurofibromatosis (von Recklinghausen’s disease). Cancer

1963;16(8):1015–1027.

155. Smith AC, Squire JA, Thorner P, et al. Association of alveolar rhabdomyosarcoma with the

Beckwith–Wiedemann syndrome. Pediatr Dev Pathol 2001;4(6):550–558.

156. Grufferman S, Schwartz AG, Ruymann FB, et al. Parents’ use of cocaine and marijuana and

increased risk of rhabdomyosarcoma in their children. Cancer Causes Control 1993;4(3):217–224.

157. Newton WA, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related

sarcomas. Pathologic aspects and proposal for a new classification—an intergroup

rhabdomyosarcoma study. Cancer 1995;76(6):1073–1085.

158. Qualman SJ, Coffin CM, Newton WA, et al. Intergroup rhabdomyosarcoma study: update for

pathologists. Pediatr Dev Pathol 1998;1(6):550–561.

159. Peydró-Olaya A, Llombart-Bosch A. Electron microscopy and other ancillary techniques in the

diagnosis of small round cell tumors. Semin Diagn Pathol 2003;20(1):25–45.

160. Turc-Carel C, Lizard-Nacol S, Justrabo E, et al. Consistent chromosomal translocation in alveolar

rhabdomyosarcoma. Cancer Genet Cytogenet 1986;19(3–4):361–362.

161. Barr FG, Galili N, Holick J, et al. Rearrangement of the PAX3 paired box gene in the paediatric

solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993;3(2):113–117.

162. Barr FG, Nauta LE, Davis RJ, et al. In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion

genes in alveolar rhabdomyosarcoma. Hum Mol Genet 1996;5(1):15–21.

163. Scrable HJ, Witte DP, Lampkin BC, et al. Chromosomal localization of the human

rhabdomyosarcoma locus by mitotic recombination mapping. Nature 1987;329(6140):645–647.

164. Scrable H, Cavenee W, Ghavimi F, et al. A model for embryonal rhabdomyosarcoma tumorigenesis

that involves genome imprinting. Proc Natl Acad Sci USA 1989;86(19):7480–7484.

165. Bridge JA, Liu J, Qualman SJ, et al. Genomic gains and losses are similar in genetic and histologic

subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia

and alveolar subtypes. Genes Chromosomes Cancer 2002;33(3):310–321.

166. Pappo A, Barr FG, Wolden SL. Pediatric rhabdomyosarcoma: biology and results of the North

American intergroup rhabdomyosarcoma trials. In: Pappo A, ed. Pediatric Bone and Soft Tissue

Sarcomas. Vol Pediatric Oncology. Berlin, Heidelberg: Springer Berlin Heidelberg; 2006:103–132.

167. Klem ML, Grewal RK, Wexler LH, et al. PET for staging in rhabdomyosarcoma: an evaluation of

PET as an adjunct to current staging tools. J Pediatr Hematol Oncol 2007;29(1):9–14.

168. Lawrence W, Anderson JR, Gehan EA, et al. Pretreatment TNM staging of childhood

rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children’s Cancer

Study Group. Pediatric Oncology Group. Cancer 1997;80(6):1165–1170.

169. Maurer HM, Crist W, Lawrence W, et al. The intergroup rhabdomyosarcoma study I. A final report.

Cancer 1988;61(2):209–220.

170. Meza JL, Anderson J, Pappo AS, et al. Children’s Oncology Group. Analysis of prognostic factors in

patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies

III and IV: the Children’s Oncology Group. J Clin Oncol 2006;24(24):3844–3851.

171. Maurer HM, Gehan EA, Beltangady M, et al. The intergroup rhabdomyosarcoma study II. Cancer

1993;71(5):1904–1922.

172. Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children’s Oncology Group (COG)

Soft Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood

Cancer 2012;59(1):5–10.

173. Raney RB, Walterhouse DO, Meza JL, et al. Results of the Intergroup Rhabdomyosarcoma Study

Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and

radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a

report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol

2011;29(10):1312–1318.

3113